[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 40, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 806716, "exercisedValue": 2177540, "unexercisedValue": 222044}, {"maxAge": 1, "name": "Ms. Tina Marriott Larson", "age": 48, "title": "COO & President", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 702244, "exercisedValue": 397610, "unexercisedValue": 5431264}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 41, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Secora Ph.D.", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 629782, "exercisedValue": 3620625, "unexercisedValue": 8705478}, {"maxAge": 1, "name": "Dr. David J. Mauro M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 674737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 40, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Hatfield", "title": "Chief Legal Officer & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Kelly", "title": "Chief Communications Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.16, "open": 7.17, "dayLow": 7.13, "dayHigh": 7.66, "regularMarketPreviousClose": 7.16, "regularMarketOpen": 7.17, "regularMarketDayLow": 7.13, "regularMarketDayHigh": 7.66, "beta": 0.828, "forwardPE": -4.0531917, "volume": 5043221, "regularMarketVolume": 5043221, "averageVolume": 5642561, "averageVolume10days": 5789610, "averageDailyVolume10Day": 5789610, "bid": 7.62, "ask": 7.65, "bidSize": 1100, "askSize": 1700, "marketCap": 2150653696, "fiftyTwoWeekLow": 4.97, "fiftyTwoWeekHigh": 15.74, "priceToSalesTrailing12Months": 43.32938, "fiftyDayAverage": 7.8171, "twoHundredDayAverage": 9.0153, "currency": "USD", "enterpriseValue": 1756513280, "floatShares": 246375462, "sharesOutstanding": 275070016, "sharesShort": 50366647, "sharesShortPriorMonth": 44919972, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.1792, "heldPercentInsiders": 0.045619998, "heldPercentInstitutions": 0.89769, "shortRatio": 10.51, "shortPercentOfFloat": 0.2502, "bookValue": 2.08, "priceToBook": 3.6634617, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -374926016, "trailingEps": -1.66, "forwardEps": -1.88, "pegRatio": -0.36, "enterpriseToRevenue": 35.389, "enterpriseToEbitda": -4.813, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RXRX", "underlyingSymbol": "RXRX", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1618579800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b61b6c65-adf4-3158-aa09-6b9439d85de8", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.62, "targetHighPrice": 16.0, "targetLowPrice": 4.5, "targetMeanPrice": 10.56, "targetMedianPrice": 10.5, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 8, "totalCash": 474340992, "totalCashPerShare": 1.688, "ebitda": -364948000, "totalDebt": 89876000, "quickRatio": 5.54, "currentRatio": 6.068, "totalRevenue": 49635000, "debtToEquity": 15.378, "revenuePerShare": 0.218, "returnOnAssets": -0.34351003, "returnOnEquity": -0.71182996, "freeCashflow": -226711248, "operatingCashflow": -331516000, "revenueGrowth": 0.309, "operatingMargins": -6.9739203, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-22"}]